Muscle Scan as an ALS Biomarker
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests a device called Myolex mScan that measures muscle health non-invasively in people with ALS. It aims to see if this can be a useful biomarker to track the disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ALS (Lou Gehrig's disease).
- Your ALS symptoms started within the last 3 years.
- Your breathing is strong enough (lung function test shows at least 40% of normal).
- You have internet access at home for uploading data.
- A family member or friend can go with you to study visits.
- You are 18 years or older and do not have severe swelling or a pacemaker that could affect the measurements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with ALS and healthy volunteers to measure how specific body fluids, symptoms, and at-home tracking change over time. It may help researchers find early signs of disease changes and better ways to measure treatment effects.
This trial uses MRI scans to look for “imaging biomarkers” (scan patterns that may help track ALS). It may help researchers better understand disease changes over time and how ALS progresses.
This study measures how well your nerves and muscles work together to see if it can serve as an early sign (a “biomarker”) of ALS. It may help doctors track ALS more accurately, especially in people who already seem to have ALS based on nerve testing.
This study uses MRI brain scans to understand how ALS affects the brain over time. It may help researchers develop better ways to measure the disease.
This study uses a wearable device to track movement patterns in people with ALS. It aims to better understand how the disease affects movement over time, which may help improve care.
This study continuously measures activity and movement in people with ALS and in control participants. It aims to better understand how muscle disease changes day-to-day function, which may help improve future monitoring or care.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.